Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gilead Sciences

Inovio Pharmaceuticals

Novavax

Regeneron Pharmaceuticals

These companies are leading the way with treatments and vaccines for the novel coronavirus.

5 Biotech Stocks Winning the Coronavirus Race

Abbott Labs

Johnson & Johnson

Vanguard Health Care ETF

SPDR S&P Biotech ETF

In this episode of ETF Spotlight, I speak with biotech expert Brad Loncar, about latest developments in coronavirus testing, vaccines and treatments.

Coronavirus Testing, Vaccines & Treatments: What You Should Know

American States Water

Citrix Systems

Amplify Mobile Payments ETF

iShares Core S&P 500 ETF

PayPal

Utilities Select Sector SPDR Fund

Health Care Select Sector SPDR Fund

SPDR S&P Software & Services ETF

These sectors are extremely well-positioned to survive market shocks. Buy the related ETFs and stocks.

4 Good Quality Sector ETFs & Stocks to Buy Right Now

AstraZeneca

BioNTech SE

GlaxoSmithKline

Pfizer

Sanofi

Telesis Bio Inc

Biotech and big pharma are putting vaccines using messenger RNA to the coronavirus test.

Is mRNA the Key to a Coronavirus Vaccine?

Why Moderna's Prospects Still Look Great

Digital Realty Trust

General Mills

Hormel Foods

Kroger

Teladoc

Zoom Video

Zscaler

Despite a rising number of U.S. coronavirus (COVID-19) cases and deaths, the SPDR S&P 500 ETF Trust (NYSE: SPY) has rallied 12.6% in the past two weeks.

10 Short Squeeze Candidates If The Market Rally Continues

Clorox

Campbell Soup

Netflix

The stocks of companies that have obtained some sort of perceived benefit from the outbreak of the novel coronavirus (Covid-19) have soared over the past couple of months as the rest of the market has tanked.

Why You Might Want to Avoid 'Virus Stocks'

Even with the sense of urgency surrounding coronavirus treatments, developers need to worth their way through the regulatory process, one that dictates it could be a year or more before a COVID-19 vaccine, such as Moderna's mRNA-1273, could be made available to patients. As such, it could be another couple of months before the company's Phase 1 data is made public.

Moderna Emerges as Coronavirus Vaccine Leader

Moderna (MRNA) is making significant progress in development of coronavirus vaccine.  It is actively preparing for a potential phase II study.

Moderna Stock Surges 78% YTD on Coronavirus Vaccine Progress

Costco

Peloton

A one-time $1,200 cash payment from the federal government is widely expected to arrive around the middle of April. Here's how to use it -

5 Top Stocks to Buy With the $1,200 Coronavirus Stimulus Check

The coronavirus vaccine developer is moving fast.

Why Moderna Stock Gained 15.5% in March While the Market Plunged

The present scenario has brightened up prospects for companies working on potential drugs and vaccines to combat the pandemic.

Coronavirus Drug & Vaccine: 4 Companies Leading From the Front

The second phase of the clinical trials of the novel coronavirus (COVID-19) vaccine of Moderna Inc.

Moderna Coronavirus Vaccine Phase 2 Trials Could Start In Spring, Chairman Says

"We'll enter hopefully phase 2 trials, we expect that to happen in the spring, perhaps early summer," Moderna Chairman Noubar Afeyan told CNBC.

Phase 2 of coronavirus vaccine human trials may begin in spring, Moderna chairman says

If you bought MRNA stock for its CMV prospects before the outbreak, consider now the time to sell. With COVID-19 speculators more than pricing in upside, cashing out today could be the best call.

Sell MRNA Stock as COVID-19 Catalyst Inflates Valuation

Given the urgent need for preventing the spread of COVID-19 in future, let's take a look at the companies developing vaccines for the same.

Coronavirus Vaccine Race Intensifies: 3 Stocks in Focus

Here's why these two pharma giants can carry you through the COVID-19 pandemic and beyond.

My Top Pharma Stocks to Buy in the Market Crash

The clinical trials of Moderna Inc.'s (NASDAQ: MRNA) novel coronavirus (COVID-19) vaccine are "on track," according to National Institute of Allergy and Infectious Diseases Director Anthony Fauci.

Moderna Coronavirus Vaccine Clinical Trials Are 'On Track,'  White House Task Force's Fauci Says

If you buy Moderna today, you're betting on the mRNA technology behind it, not its coronavirus vaccine. 
The post Any COVID-19 Vaccine Upside Already Is Built Into MRNA Stock appeared first on InvestorPlace.

Any COVID-19 Vaccine Upside Already Is Built Into MRNA Stock

As of late, it has definitely been a great time to be an investor Moderna

Will Moderna Continue to Surge Higher?

The coronavirus pandemic has hit markets bad. But investors shouldn't shun stocks in April but should instead look for avenues to invest in areas under focus owing to rise in infected cases.

Top Stock Trades to Beat Coronavirus Blues in April

CRISPR Therapeutics

Vir Biotechnology

These biotech stocks are all working on treatments that have the potential to beat the coronavirus. Don't just wait for a cure.

7 Biotech Stocks to Buy That Could Beat the Coronavirus

Bristol-Myers

Eli Lilly

Vertex Pharmaceuticals

Postponed clinical trials might mean a longer time-to-market for certain drugs.

Do Clinical Trial Delays Mean Trouble for Pharmaceutical Stocks?

Vaxart

Just like the flu vaccine, pharmacists should be empowered to administer the COVID-19 vaccine to patients in every state.

Expand Pharmacists’ Authority To Promote COVID-19 Vaccine Access

The U.S. government has cut deals with Johnson & Johnson  and Moderna Inc  and said it is in talks with at least two other companies to prepare them to produce massive quantities of coronavirus vaccines even before safe and effective ones become available.

News for Moderna Stock (MRNA)